Many drugs targeting various components of TME have been approved for clinical therapy, including aromatase, vascular endothelial growth factor (VEGF), and immune checkpoint inhibitors (ICIs), which gained outstanding achievements in the treatment of NSCLC.20 This evidence concerns the gene CYP19A1 and non-small cell lung carcinoma.